Samrat Pharmachem Ltd.
BSE: SAMRATPH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Samrat Pharmachem Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Samrat Pharmachem Limited is an Indian manufacturer specialising in the production and export of iodine salts and bromine derivatives. The company serves diverse sectors including pharmaceuticals, food processing, and chemical synthesis from its primary facility in Ankleshwar, Gujarat.
Business Model
The company generates revenue through the manufacturing and global distribution of specialised chemical compounds. It leverages its synthesis capabilities to supply industrial clients across North America, Europe, and Asia.
Growth Outlook
Growth is driven by the expansion of chemical synthesis capabilities and the strengthening of its international export footprint. The company continues to focus on maintaining high quality standards to meet evolving industrial requirements.
Key Risks
- Raw Material Price Volatility. Fluctuations in the global prices of iodine and bromine can significantly impact the company's production costs and profit margins.
- Regulatory Compliance. The company must adhere to stringent international and domestic environmental and pharmaceutical manufacturing standards, which may increase operational costs.
- Foreign Exchange Risk. As a significant exporter, the company is exposed to currency fluctuations that may affect the competitiveness and profitability of its international sales.
- Geopolitical Instability. Global supply chain disruptions or trade barriers in key export markets like North America and Europe could adversely affect revenue streams.
Start your research today
Unlock AI insights, financials, peers and live data on Samrat Pharmachem Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹281 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹19.65
TTM · standalone
RETURN ON EQUITY
9.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.3%
TTM · standalone
P/E
13.1x
Q1 FY26 · standalone
EV/EBITDA
7.4x
Q1 FY26 · standalone
EBITDA MARGIN
3.4%
TTM · standalone
NET PROFIT MARGIN
0.7%
Q3 FY26 · standalone
DEBT TO EQUITY
0.1x
Q2 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Samrat Pharmachem Ltd.SAMRATPH | ₹74 Cr | 12.26 | 8.78 | -7.9% | 3.4% | 9.1% | 13.3% | -25.9% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q1 FY26
Financials
Samrat Pharmachem Ltd.
BSE: SAMRATPH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Samrat Pharmachem Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Samrat Pharmachem Limited is an Indian manufacturer specialising in the production and export of iodine salts and bromine derivatives. The company serves diverse sectors including pharmaceuticals, food processing, and chemical synthesis from its primary facility in Ankleshwar, Gujarat.
Business Model
The company generates revenue through the manufacturing and global distribution of specialised chemical compounds. It leverages its synthesis capabilities to supply industrial clients across North America, Europe, and Asia.
Growth Outlook
Growth is driven by the expansion of chemical synthesis capabilities and the strengthening of its international export footprint. The company continues to focus on maintaining high quality standards to meet evolving industrial requirements.
Key Risks
- Raw Material Price Volatility. Fluctuations in the global prices of iodine and bromine can significantly impact the company's production costs and profit margins.
- Regulatory Compliance. The company must adhere to stringent international and domestic environmental and pharmaceutical manufacturing standards, which may increase operational costs.
- Foreign Exchange Risk. As a significant exporter, the company is exposed to currency fluctuations that may affect the competitiveness and profitability of its international sales.
- Geopolitical Instability. Global supply chain disruptions or trade barriers in key export markets like North America and Europe could adversely affect revenue streams.
Start your research today
Unlock AI insights, financials, peers and live data on Samrat Pharmachem Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹281 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹19.65
TTM · standalone
RETURN ON EQUITY
9.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.3%
TTM · standalone
P/E
13.1x
Q1 FY26 · standalone
EV/EBITDA
7.4x
Q1 FY26 · standalone
EBITDA MARGIN
3.4%
TTM · standalone
NET PROFIT MARGIN
0.7%
Q3 FY26 · standalone
DEBT TO EQUITY
0.1x
Q2 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY26